Potassium Chloride Extended-Release Tablets are indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient.
Potassium chloride is contraindicated in patients on triamterene and amiloride.
Potassium chloride is contraindicated in patients on triamterene and amiloride.
Potassium Chloride Extended-Release Tablets, USP are supplied as: The 8 mEq (600 mg) tablets are white to off-white, round, biconvex, coated tablets, debossed with “YH” and “106” on one side, and “8” on the other side. The 10 mEq (750 mg) tablets are white to off-white, round, biconvex, coated tablets, debossed with “YH” and “105” on one side, and “10” on the other side.
Potassium Chloride Extended-Release Tablets, USP contain 600 mg or 750 mg of Potassium Chloride, USP (equivalent to 8 mEq and 10 mEq respectively), and are provided as extended release tablets. Table 1: How Supplied Dose Shape Color Debossment Bottle of 100 tablets Bottle of 500 tablets Bottle of 1000 tablets 600 mg (8 mEq) Round White to off-white “YH” and “106” on one side, and “8” on the other side 42806-422-01 42806-422-05 42806-422-10 750 mg (10 mEq) Round White to off-white “YH” and “105” on one side, and “10” on the other side 42806-423-01 42806-423-05 42806-423-10 Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature.] Protect from light and moisture. Dispense in a tight container as defined in the USP with a child-resistant closure.
NDC 71610-945 - Potassium Chloride ER, USP 10mEq (750mg) Tablets - Rx Only
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 628953 | potassium chloride 10 MEQ (750 MG) Extended Release Oral Tablet | PSN | 1 |
| 628953 | potassium chloride 10 MEQ Extended Release Oral Tablet | SCD | 1 |
| 628953 | K+ Chloride 10 MEQ Extended Release Oral Tablet | SY | 1 |
| 628953 | Pot Chloride 10 MEQ Extended Release Oral Tablet | SY | 1 |
| 628953 | potassium chloride 750 MG (potassium 10 mEq) Extended Release Oral Tablet | SY | 1 |
| 628953 | potassium chloride 750 MG Extended Release Oral Tablet | SY | 1 |
| Class | Version | Type | Effective |
|---|---|---|---|
| POTASSIUM CATION Pharmacologic Class Indexing | 3 | Indexing - Pharmacologic Class | 20180813 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 71610-945-30 | Potassium Chloride | 30 in 1 BOTTLE | TABLET, FILM COATED, EXTENDED RE | 30 | 1 | |
| 71610-945-53 | Potassium Chloride | 60 in 1 BOTTLE | TABLET, FILM COATED, EXTENDED RE | 60 | 1 | |
| 71610-945-60 | Potassium Chloride | 90 in 1 BOTTLE | TABLET, FILM COATED, EXTENDED RE | 90 | 1 | |
| 71610-945-70 | Potassium Chloride | 120 in 1 BOTTLE | TABLET, FILM COATED, EXTENDED RE | 120 | 1 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 71610-945-30 | EA - Each | 71610-945 | e9b857c0-c24b-4938-84e3-dc6300ef2e35 | 1 | 2025-10-14 |
| 71610-945-53 | EA - Each | 71610-945 | c0d915ff-f55e-4788-953b-71e47ee90de4 | 1 | 2025-10-14 |
| 71610-945-60 | EA - Each | 71610-945 | 660e57d9-dffa-4286-9d1c-e9f41d4bed77 | 1 | 2025-10-14 |
| 71610-945-70 | EA - Each | 71610-945 | 732aa1bb-d351-413f-a35d-b2c94fa7cdc3 | 1 | 2025-10-14 |
| 42806-423-01 | EA - Each | 42806-423 | 8594d722-482d-45e7-bb33-4174063230db | 1 | 2023-09-05 |
| 42806-423-05 | EA - Each | 42806-423 | 893dd363-a943-4dbd-ba44-06b43712428b | 1 | 2023-09-05 |
| 42806-423-10 | EA - Each | 42806-423 | 9a17180f-7ddc-4f8d-a663-6709fd2fb169 | 1 | 2023-09-05 |
| Name | UNII | Kind |
|---|---|---|
| HYDROGENATED COTTONSEED OIL | Z82Y2C65EA | IACT |
| HYDROXYPROPYL CELLULOSE, UNSPECIFIED | 9XZ8H6N6OH | IACT |
| SILICON DIOXIDE | ETJ7Z6XBU4 | IACT |
| POLYVINYL ALCOHOL | 532B59J990 | IACT |
| TITANIUM DIOXIDE | 15FIX9V2JP | IACT |
| POLYETHYLENE GLYCOL, UNSPECIFIED | 3WJQ0SDW1A | IACT |
| LECITHIN, SOYBEAN | 1DI56QDM62 | IACT |
| TALC | 7SEV7J4R1U | IACT |
| POTASSIUM CHLORIDE | 660YQ98I10 | ACTIM |
Potassium Chloride Extended-Release Tablets are indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient.
Potassium Chloride Extended-Release Tablets, USP are supplied as: The 8 mEq (600 mg) tablets are white to off-white, round, biconvex, coated tablets, debossed with “YH” and “106” on one side, and “8” on the other side. The 10 mEq (750 mg) tablets are white to off-white, round, biconvex, coated tablets, debossed with “YH” and “105” on one side, and “10” on the other side.
Potassium chloride is contraindicated in patients on triamterene and amiloride.
Potassium Chloride Extended-Release Tablets, USP are a solid oral dosage form of potassium chloride. Each contains 600 mg or 750 mg of potassium chloride equivalent to 8 mEq or 10 mEq of potassium in a wax matrix tablet. Potassium Chloride Extended-Release Tablets, USP are an electrolyte replenisher. The chemical name is potassium chloride, and the structural formula is KCl. Potassium chloride, USP is a white, granular powder or colorless crystals. It is odorless and has a saline taste. Its solutions are neutral to litmus. It is freely soluble in water and insoluble in alcohol. Inactive Ingredients: colloidal silicon dioxide, hydroxypropyl cellulose and hydrogenated vegetable oil. The film coating contains lecithin, polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide. FDA approved dissolution test specifications differ from USP.
Potassium Chloride Extended-Release Tablets, USP contain 600 mg or 750 mg of Potassium Chloride, USP (equivalent to 8 mEq and 10 mEq respectively), and are provided as extended release tablets. Table 1: How Supplied Dose Shape Color Debossment Bottle of 100 tablets Bottle of 500 tablets Bottle of 1000 tablets 600 mg (8 mEq) Round White to off-white “YH” and “106” on one side, and “8” on the other side 42806-422-01 42806-422-05 42806-422-10 750 mg (10 mEq) Round White to off-white “YH” and “105” on one side, and “10” on the other side 42806-423-01 42806-423-05 42806-423-10 Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature.] Protect from light and moisture. Dispense in a tight container as defined in the USP with a child-resistant closure.
Inform patients to take each dose with meals and with a full glass of water or other liquid, and to not crush, chew, or suck the tablets. Inform patients that the wax matrix is not absorbed and is excreted in the feces; in some instances the empty matrices may be noticeable in the stool. Advise patients seek medical attention if tarry stools or other evidence of gastrointestinal bleeding is noticed.
Please reference the HOW SUPPLIED section listed above for a description of individual drug products listed below. This drug product has been received by Aphena Pharma Solutions - Tennessee, LLC in a manufacturer or distributor packaged configuration and repackaged in full compliance with all applicable cGMP regulations. The package configurations available from Aphena are listed below: 10mEq (750mg) NDC 71610-945-30, Bottles of 30 Tablets NDC 71610-945-53, Bottles of 60 Tablets NDC 71610-945-60, Bottles of 90 Tablets NDC 71610-945-70, Bottles of 120 Tablets Store between 20°-25°C (68°-77°F). See USP Controlled Room Temperature. Dispense in a tight light-resistant container as defined by USP. Keep this and all drugs out of the reach of children. Repackaged by: Cookeville, TN 38506 20250904AMH
NDC 71610-945 - Potassium Chloride ER, USP 10mEq (750mg) Tablets - Rx Only